Referanslar

1. Rojas KD, Perez ME, Marchetti MA, Nichols AJ, Penedo FJ, Jaimes N. Skin cancer: Primary, secondary, and tertiary pre- vention. Part II. J Am Acad Dermatol. 2022;87(2):271-288. [Crossref]  [PubMed]
2. Escudero-Góngora MM, Fernández-Peñas P. Nicotin- amide. New Indications in Dermatology. Actas Dermosi- filiogr. 2016;107(9):777-778. [Crossref]  [PubMed]
3. Stratigos A, Garbe C, Lebbe C, Malvehy J, del Marmol V, Pehamberger H, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consen- sus-based interdisciplinary guideline. Eur J Cancer. 2015;51: 1989-2007. [Crossref]  [PubMed]
4. Frydrych A, Krośniak M, Jurowski K. The Role of Cho- sen Essential Elements (Zn, Cu, Se, Fe, Mn) in Food for Special Medical Purposes (FSMPs) Dedicated to On- cology Patients-Critical Review: State-of-the-Art. Nu- trients. 2023;15(4):1012. [Crossref]  [PubMed]
5. Lahoda Brodska H, Klempir J, Zavora J, Kohout P. The Role of Micronutrients in Neurological Disorders. Nu- trients. 2023;15(19):4129. [Crossref]  [PubMed]
6. Reichrath J, Saternus R, Vogt T. Endocrine actions of vitamin D in skin: Relevance for photocarcinogenesis of non-mela- noma skin cancer, and beyond. Mol Cell Endocrinol. 2017; 453:96-102. [Crossref]  [PubMed]
7. Mason RS, Reichrath J. Sunlight vitamin D and skin cancer. Anticancer Agents Med Chem. 2013;13(1):83-97. [Crossref]
8. Holick M F, Binkley N C, Bischoff-Ferrari H A, Gordon C M, Hanley D A, Heaney R P. et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Me- tab. 2011;96(7):1911-1930. [Crossref]  [PubMed]
9. Balcı C, Toktaş N. D Vitamini Sentezi, Metabolizmasi ve Sağ- lik Üzerine Etkileri. Gazi Sağlık Bilim Derg.2021;6(1):33-47. [Link]
10. Holick MF.Vitamin D deficiency. N Engl J Med.2007; 357:266-281. [Crossref]  [PubMed]
11. Field S, Newton-Bishop JA. Melanoma and vitamin D. Mol Oncol. 2011;5(2):197-214. [Crossref]  [PubMed]
12. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1Alpha,25-dihydroxyvitamin D3 (calcitri- ol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther. 2007; 6(4): 1433-1439. [Crossref]  [PubMed]
13. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res. 2000; 87(3): 214-220. [Crossref]  [PubMed]
14. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP. Inhibition of proliferation of prostate cancer cells by a 19-NOR-hexafluoride vitamin D3 analogue involves the induction of p21WAF1, p27KIP1 and E-cadherin. J Mol En- docrinol. 1997; 19(1): 15-27. [Crossref]  [PubMed]
15. Lopes N, Carvalho J, Duraes C, Sousa B, Gomes M, Costa JL, et al. 1Alpha,25-dihydroxyvitamin D3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. Anticancer Res. 2012; 32(1): 249-257. [PubMed]
16. Hsu JW, Yasmin-Karim S, King MR, Wojciechowski JC, Mickelsen D, Blair ML, et al. Suppression of prostate cancer cell rolling and adhesion to endothelium by 1alpha,25-di- hydroxyvitamin D3. Am J Pathol. 2011;178(2): 872-880. [Crossref]  [PubMed]
17. Lin R. Crosstalk between Vitamin D Metabolism, VDR Signalling, and Innate Immunity. Biomed Res Int. 2016; 2016:1375858. [Crossref]  [PubMed]
18. Seretis K, Bounas N, Sioka C. The Association of Vitamin D with Non-Melanoma Skin Cancer Risk: An Umbrella Re- view of Systematic Reviews and Meta-Analyses. Medicina (Kaunas). 2023;59(12):2130. [Crossref]  [PubMed]
19. Reichrath J, Kamradt J, Zhu XH, Kong XF, Tilgen W, Hol- ick MF. Analysis of 1,25-dihydroxyvitamin D (3) receptors (VDR) in basal cell carcinomas. Am J Pathol. 1999; 155 (2): 583-589. [Crossref]  [PubMed]
20. Mitschele T, Diesel B, Friedrich M, Meineke V, Maas RM, Gartner BC et al. Analysis of the vitamin D system in basal cell carcinomas (BCCs). Lab Invest. 2004: 84 (6); 693-702. [Crossref]  [PubMed]
21. Bikle DD. Vitamin D receptor, a tumor suppressor in skin. Can J Physiol Pharmacol. 2015; 93 (5): 349-354. [Crossref]  [PubMed]
22. Kostner K, Denzer N, Muller CS, Klein R, Tilgen W, Re- ichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anti- cancer Res. 2009;29 (9): 3511-3536. [PubMed]
23. Kostner K, Denzer N, Koreng M, Reichrath S, Graber S, Klein R, et al. Association of genetic variants of the vitamin D receptor (VDR) with cutaneous squamous cell carcinomas (SCC) and basal cell carcinomas (BCC): a pilot study in a German population. Anticancer Res.2012; 32 (1): 327-333. [PubMed]
24. Ramachandran S, Fryer AA, Lovatt T J, Smith AG, Lear JT, Jones PW, et al. Combined effects of gender, skin type and polymorphic genes on clinical phenotype: use of rate of in- crease in numbers of basal cell carcinomas as a model sys- tem. Cancer Lett. 2003: 189 (2): 175-181. [Crossref]  [PubMed]
25. Han J, Colditz GA, Hunter DJ. Polymorphisms in the MTHFR and VDR genes and skin cancer risk. Carcinogen- esis. 2007; 28 (2): 390-397. [Crossref]  [PubMed]
26. Uhmann A, Niemann H, Lammering B, Henkel C, Hess I, Nitzki F, et al. Antitumoral effects of calcitriol in basal cell carcinomas involve inhibition of hedgehog signaling and in- duction of vitamin D receptor signaling and differentiation. Mol Cancer Ther. 2011;10(11):2179-2188. [Crossref]  [PubMed]
27. Bijlsma MF, Spek CA, Zivkovic D, van de Water S, Re- zaee F, Peppelenbosch MP. Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLoS Biol. 2006;4(8):e232. [Crossref]  [PubMed]
28. Abdelwahab R, Huang R, Potla S, Bhalla S, AlQabandi Y, Nandula SA, et al. The Relationship between Vitamin D and Basal Cell Carcinoma: A Systematic Review. Cureus. 2022;14(9):e29496. [Crossref]  [PubMed]
29. Caini S, Gnagnarella P, Stanganelli I, Bellerba F, Coco- rocchio E, Queirolo P, et al. Vitamin D and the Risk of Non-Melanoma Skin Cancer: A Systematic Literature Re- view and Meta-Analysis on Behalf of the Italian Melano- ma Intergroup. Cancers (Basel). 2021;13(19):4815. [Crossref]  [PubMed]
30. Mahamat-Saleh Y, Aune D, Schlesinger S. 25-Hydroxyvi- tamin D status, vitamin D intake, and skin cancer risk: a systematic review and dose-response meta-analysis of pro- spective studies. Sci Rep. 2020;10(1):13151. [Crossref]  [PubMed]
31. Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvita- min D3 and malignant melanoma: The presence of recep- tors and inhibition of cell growth in culture. Endocrinolo- gy. 1981; 108(3): 1083-1086. [Crossref]  [PubMed]
32. Brożyna AA, Hoffman RM, Slominski AT. Relevance of Vi- tamin D in Melanoma Development, Progression and Therapy. Anticancer Res. 2020 ;40(1):473-489. [Crossref]  [PubMed]
33. Cattaruzza MS, Pisani D, Fidanza L, Gandini S, Marmo G, Narcisi A, et al. 25-hydroxyvitamin D serum levels and melanoma risk: A case-control study and evidence syn- thesis of clinical epidemiological studies. Eur J Cancer Prev. 2019;28(3):203-211. [Crossref]  [PubMed]
34. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol. 2009: 27(32); 5439-5444. [Crossref]  [PubMed]
35. Wyatt C, Lucas RM, Hurst C, Kimlin MG. Vitamin D de- ficiency at melanoma diagnosis is associated with high- er Breslow thickness. PLoS One. 2015: 10(5); e0126394. [Crossref]  [PubMed]
36. Bade B, Zdebik A, Wagenpfeil S, Graber S, Geisel J, Vogt T, et al. Low serum 25-hydroxyvitamin D concentrations are associated with increased risk for melanoma and unfa- vourable prognosis. PLoS One.2014: 9(12); e112863, [Crossref]  [PubMed]
37. Lim A, Shayan R, Varigos G: High serum vitamin D level correlates with better prognostic indicators in primary mela- noma: A pilot study. Australas J Dermatol. 2018; 59(3): 182-187. [Crossref]  [PubMed]
38. Saiag P, Aegerter P, Vitoux D, Lebbé C, Wolkenstein P, Dup- in N, et al. Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients. J Natl Cancer Inst. 2015;107(12):djv264. [Crossref]  [PubMed]
39. Nürnberg B, Gräber S, Gärtner B, Geisel J, Pföhler C, Schadendorf D, et al. Reduced serum 25-hydroxyvita- min D levels in stage IV melanoma patients. Anticancer Res. 2009;29(9):3669-3674. [PubMed]
40. Verdin E. NAD+ in aging, metabolism, and neurodegener- ation. Science. 2015;350:1208-1213. [Crossref]  [PubMed]
41. Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012; 13:411-424. [Crossref]  [PubMed]
42. Escudero-Góngora MM, Fernández-Peñas P. Nicotin-amide: New Indications in Dermatology. Actas Dermosi- filiogr. 2016;107(9):777-778. [Crossref]  [PubMed]
43. Hyeraci M, Papanikolau ES, Grimaldi M, Ricci F, Pallotta S, Monetta R, et al. Systemic Photoprotection in Melanoma and Non-Melanoma Skin Cancer. Biomolecules. 2023 Jul 2;13(7):1067. [Crossref]  [PubMed]
44. Jamison A, Malhotra R. Nicotinamide and Nonmelanoma Skin Cancers. Ophthalmic Plast Reconstr Surg. 2022;38(3):304-305. [Crossref]  [PubMed]
45. Hunt SV, Jamison A, Malhotra R. Oral nicotinamide for non-melanoma skin cancers: A review. Eye (Lond). 2023;37(5):823-829. [Crossref]  [PubMed]
46. Sailo BL, Banik K, Padmavathi G, Javadi M, Bordoloi D, Kunnumakkara AB. Tocotrienols: The promising an- alogues of vitamin E for cancer therapeutics. Pharmacol Res. 2018;130:259-272. [Crossref]  [PubMed]
47. Marzagalli M, Moretti RM, Messi E, Marelli MM, Fon- tana F, Anastasia A, et al. Targeting melanoma stem cells with the Vitamin E derivative -tocotrienol. Sci Rep. 2018;8(1):587. [Crossref]  [PubMed]
48. McNaughton SA, Marks GC, Green AC. Role of dietary factors in the development of basal cell cancer and squa- mous cell cancer of the skin. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1596-1607. [Crossref]  [PubMed]
49. Pullar JM, Carr AC, Vissers MCM. The Roles of Vitamin C in Skin Health. Nutrients. 2017 Aug 12;9(8):866. [Crossref]  [PubMed]
50. Pernice C, Murri D, Valli R, Crocetta FM, Iori M, Asti M, et al. Complete response of cutaneous SCC to topical treat- ment with ascorbic acid solution: A case report. Clin Case Rep. 2021;9:1060-1065. [Crossref]  [PubMed]
51. Holló P, Jókai H, Hársing J, Soós G, Kárpáti S, NémethK. Topically applied ascorbic acid solution for the treat- ment of basal cell carcinoma (BCC). J Am Acad Derma- tol. 2016;75(1):212-213. [Crossref]  [PubMed]
52. Capponi PC, Murri D, Pernice C. Topical L-Ascorbic Acid Formulation for a Better Management of Non-Melanoma Skin Cancer: Perspective for Treatment Strategies. Phar- maceutics. 202;13(8):1201. [Crossref]  [PubMed]
53. Jackson MJ. Physiology of zinc: General aspects. Mills CF, editor. Zinc in Human Biology. 1st edition. Spring- er; 1989. p. 1-14. [Crossref]
54. Rostan EF, DeBuys HV, Madey DL, Pinnell SR. Evidence supporting zinc as an important antioxidant for skin. Int J Dermatol. 2002;41(9):606-611. [Crossref]  [PubMed]
55. Thompson KG, Kim N. Dietary supplements in derma- tology: A review of the evidence for zinc, biotin, vitamin D, nicotinamide, and Polypodium. J Am Acad Derma- tol. 2021;84(4):1042-1050. [Crossref]  [PubMed]
56. Razaghi A, Poorebrahim M, Sarhan D, Björnstedt M. Sele- nium stimulates the antitumour immunity: Insights to future research. Eur J Cancer. 2021;155:256-267. [Crossref]  [PubMed]
57. Rogoża-Janiszewska E, Malińska K, Baszuk P, Marcin- iak W, Derkacz R, Lener M, et al. Serum Selenium Lev- el and 10-Year Survival after Melanoma. Biomedicines. 2021;9(8):991. [Crossref]  [PubMed]
58. Pence BC, Delver E, Dunn DM. Effects of dietary selenium on UVB-induced skin carcinogenesis and epidermal antioxi- dant status. J Invest Dermatol. 1994;102(5):759-761. [Crossref]  [PubMed]
59. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF Jr, et al. Nutritional Prevention of Cancer Study Group. Selenium supplementation and second- ary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst. 2003;95(19):1477-1481. [Crossref]  [PubMed]
60. Cassidy PB, Fain HD, Cassidy JP Jr, Tran SM, Moos PJ, Boucher KM, et al. Selenium for the prevention of cutaneous melanoma. Nutrients. 2013;5(3):725-749. [Crossref]  [PubMed]
61. Vinceti M, Filippini T, Del Giovane C, Dennert G, Zwahlen M, Brinkman M, et al. Selenium for preventing cancer. Co- chrane Database Syst Rev. 2018;1(1):CD005195. [PubMed]
62. Takahashi N, Saito D, Hasegawa S, Yamasaki M, Imai M. Vitamin A in health care: Suppression of growth and induc- tion of differentiation in cancer cells by vitamin A and its derivatives and their mechanisms of action. Pharmacol Ther. 2022;230:107942. [Crossref]  [PubMed]
63. Doldo E, Costanza G, Agostinelli S, Tarquini C, Ferlosio A, Arcuri G, et al. Vitamin A, cancer treatment and prevention: the new role of cellular retinol binding proteins. Biomed Res Int. 2015; 2015:624627. [Crossref]  [PubMed]
64. Wei Q, Matanoski GM, Farmer ER, Strickland P, GrossmanL. Vitamin supplementation and reduced risk of basal cell carcinoma. J Clin Epidemiol. 1994;47:829-836. [Crossref]  [PubMed]
65. Davies TW, Treasure FP, Welch AA, Day NE. Diet and basal cell skin cancer: results from the EPIC-Norfolk cohort. Br J Dermatol. 2002;146: 1017-1022. [Crossref]  [PubMed]
66. Hunter DJ, Colditz GA, Stampfer MJ, Rosner B, Willett WC, Speizer FE. Diet and risk of basal cell carcinoma of the skin in a prospective cohort of women. Ann Epide- miol. 1992;2(3):231-239. [Crossref]  [PubMed]
67. van Dam RM, Huang Z, Giovannucci E, Rimm EB, Hunter DJ, Colditz GA, et al. Diet and basal cell carcino- ma of the skin in a prospective cohort of men. Am J Clin Nutr. 2000;71(1):135-141. [Crossref]  [PubMed]
68. Breslow RA, Alberg AJ, Helzlsouer KJ, Bush TL, Norkus EP, Morris JS, et al. Serological precursors of cancer: malignant melanoma, basal and squamous cell skin cancer, and prediagnostic levels of retinol, beta- carotene, lycopene, al- pha-tocopherol, and selenium. Cancer Epidemiol Biomark- ers Prev. 1995;4(8):837-842. [PubMed]
69. Moon TE, Levine N, Cartmel B, Bangert JL, Rodney S, Dong Q, et al. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev. 1997;6(11):949-956. [PubMed]